{"id":"NCT02337764","sponsor":"Takeda","briefTitle":"A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants","officialTitle":"A Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-03","primaryCompletion":"2016-09-29","completion":"2016-09-29","firstPosted":"2015-01-14","resultsPosted":"2019-04-19","lastUpdate":"2022-03-02"},"enrollment":222,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"TVP-1012 1mg","otherNames":[]}],"arms":[{"label":"TVP-1012 1mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate long-term safety of TVP-1012 (1 mg/day) with levodopa in Japanese participants with Parkinson's disease.","primaryOutcome":{"measure":"Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","timeFrame":"Up to Week 52","effectByArm":[{"arm":"TVP-1012 1 mg","deltaMin":185,"sd":null}],"pValues":[]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":26},"locations":{"siteCount":24,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":222},"commonTop":["Fall","Nasopharyngitis","Dyskinesia","Contusion","Orthostatic hypotension"]}}